Loading...
XNAS
VOR
Market cap293mUSD
Jul 29, Last price  
2.35USD
1D
-2.89%
1Q
246.05%
IPO
-94.51%
Name

Vor Biopharma Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
13.10%
Rev. gr., 5y
%
Revenues
0k
Net income
-117m
L-0.81%
-4,152,000-11,447,000-43,337,000-68,780,000-90,770,000-117,863,000-116,914,000
CFO
-100m
L-0.63%
-2,661,000-9,855,000-36,292,000-69,144,000-85,144,000-100,292,000-99,660,000
Earnings
Aug 06, 2025

Profile

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
IPO date
Feb 05, 2021
Employees
133
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
121,185
129,528
102,378
Unusual Expense (Income)
NOPBT
(121,185)
(129,528)
(102,378)
NOPBT Margin
Operating Taxes
(1,324)
Tax Rate
NOPAT
(121,185)
(129,528)
(101,054)
Net income
(116,914)
-0.81%
(117,863)
29.85%
(90,770)
31.97%
Dividends
Dividend yield
Proceeds from repurchase of equity
55,825
3,391
115,975
BB yield
-73.20%
-2.24%
-44.09%
Debt
Debt current
4,215
7,660
3,272
Long-term debt
59,445
67,490
74,552
Deferred revenue
Other long-term liabilities
Net debt
(28,266)
(62,025)
(154,834)
Cash flow
Cash from operating activities
(99,660)
(100,292)
(85,144)
CAPEX
(229)
(1,069)
(8,462)
Cash from investing activities
96,857
71,008
(94,091)
Cash from financing activities
53,392
2,938
117,140
FCF
(112,675)
(122,548)
(135,609)
Balance
Cash
91,926
137,175
230,245
Long term investments
2,413
Excess cash
91,926
137,175
232,658
Stockholders' equity
(456,959)
(340,150)
(222,980)
Invested Capital
585,453
530,364
512,499
ROIC
ROCE
EV
Common stock shares outstanding
68,706
67,192
39,551
Price
1.11
-50.67%
2.25
-66.17%
6.65
-42.77%
Market cap
76,263
-49.56%
151,182
-42.52%
263,017
-39.11%
EV
47,997
89,157
108,183
EBITDA
(117,657)
(126,036)
(99,853)
EV/EBITDA
Interest
1,324
Interest/NOPBT